Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis Clinical Trial

Official title:

A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05177835
• Other study ID #: ABX464-108
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 3, 2021
• Est. completion date: April 2027

Study information

• Verified date: December 2023
• Source: Abivax S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment. All subjects will receive ABX464 given at 25 mg QD. The enrolment in this long-term study will be based on the endoscopic improvement, the willingness of the subject to carry on his/her participation and also based on investigator's judgement. Subjects will be treated with ABX464 for a maximum period of 54 months. Subjects will be followed up quarterly. After the treatment period, subjects will be followed for 4 additional weeks for safety purposes.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 203
• Est. completion date: April 2027
• Est. primary completion date: February 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects who previously completed the ABX464-102 or ABX464-104 clinical studies
• Subjects should be in endoscopic improvement with a rectal bleeding sub-score = 0 point at the end of treatment period in the previous study (ABX464-102 or ABX464-104). Endoscopic improvement is defined as: a Mayo endoscopic sub score of =1 ;
• Subjects able and willing to comply with study visits and procedures;
• Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures;
• 5. Women of childbearing potential and men receiving the study treatment and their partners must agree to continue a highly effective contraceptive method during the study and for 6 months (180 days) after end of study or early termination. Women must be surgically sterile or if of childbearing potential must use a highly effective contraceptive method. Women of childbearing potential (WOCBP) will enter the study after confirmed menstrual period and a negative pregnancy test. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation, intrauterine hormone releasing system, bilateral tubal ligation, vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject. In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is required. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycle. Female and male subjects must not be planning pregnancy during the trial and for 6 months post completion of their participation in the trial. In addition, male subjects should use condom during the trial and for 6 months (180 days) post completion of their participation in the study. Male subjects must not donate sperm as long as contraception is required. For the purpose of this protocol, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. Finally, a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy;
• Subjects should be affiliated to a social security regimen (for French sites only).

Exclusion Criteria:

• Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (except UC) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study
• Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
• Subjects who are participating or plan to participate in other investigational studies (other than induction study) during the study.

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Drug:
• ABX464
All subjects will receive ABX464 given at 25 mg QD.

Locations

Country	Name	City	State
Belgium	UZ Leuven	Leuven
Czechia	Fakultni nemocnice u sv. Anny v Brne	Brno
Czechia	Nemocnice Slany	Slany
Hungary	DRC Gyogyszervizsgalo Kozpont Kft.	Balatonfured
Poland	Centrum Medyczne Plejady	Kraków
Poland	Samodzielny PZOZ w Lecznej	Leczna
Poland	Trialmed CRS	Piotrkow Trybunalski
Poland	Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska	Wroclaw

Sponsors (1)

Lead Sponsor	Collaborator
Abivax S.A.

Countries where clinical trial is conducted

Belgium,  Czechia,  Hungary,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events in ABX464 treated subjects	To evaluate the long-term safety of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.	From Baseline to a maximum period of 54 months
Secondary	Percentage of subjects reaching clinical remission at yearly visits.	To evaluate the long-term effect of ABX464 on clinical remission	From Baseline to a maximum period of 54 months
Secondary	Percentage of subjects reaching endoscopic remission at yearly visits	To evaluate the long-term effect of ABX464 on endoscopic remission	From Baseline to a maximum period of 54 months
Secondary	Percentage of subjects reaching clinical response at yearly visits	To evaluate the long-term effect of ABX464 on clinical response	From Baseline to a maximum period of 54 months
Secondary	Percentage of subjects reaching endoscopic improvement at yearly visits	To evaluate the long-term effect of ABX464 on endoscopic improvement	From Baseline to a maximum period of 54 months